563 - Safety and Immunogenicity of mRNA-1273.815 in COVID-19 Vaccine-Naïve Children 2 Through 4 Years of Age: Results From a Phase 3, Open-Label Trial

Presenting Author(s)

• 

  Avika Dixit, MBBS

  Moderna, Inc.
  Cambridge, Massachusetts, United States

Co-Author(s)

• RS

  Roozbeh Sharif, MD

  REX Clinical Trials, LLC Beaumont
  Beaumont, Texas, United States
• RP

  Rosane Poston, BS

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• GC

  Greer Chambers, BS, CPM

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• AY

  Anne Yeakey, MD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• HW

  Heather Williams, BS

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• BG

  Bethany Girard, Ph.D.

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• WZ

  Wen Zhou, PhD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• WX

  Wenqin Xu, PhD

  Moderna, Inc.
  Cambridge, Massachusetts, United States

Co-Author(s)

• SC

  Spyros Chalkias, MD (he/him/his)

  Senior Medical Director
  Moderna, Inc.
  Cambridge, MA, United States

Co-Author(s)

• FP

  Frances Priddy, MD, MPH (she/her/hers)

  Executive Director, Clinical Development
  Moderna, Inc.
  Cambridge, Massachusetts, United States
• RD

  Rituparna Das, M.D.

  Moderna, Inc.
  Cambridge, Massachusetts, United States